Can lacosamide be used to treat arthritis?

Lacosamide is NOT recommended for arthritis treatment

Lacosamide is an antiepileptic drug with no established role in arthritis management and should not be used for this indication. While emerging preclinical research shows promise, there is no guideline support or clinical evidence for its use in arthritis patients.

Why Lacosamide Should Not Be Used for Arthritis

Absence from Clinical Guidelines

None of the major arthritis management guidelines mention lacosamide as a treatment option:

• Osteoarthritis guidelines 1 recommend a stepwise approach starting with paracetamol, topical NSAIDs, oral NSAIDs/COX-2 inhibitors, and opioids for pain relief, with no mention of sodium channel blockers like lacosamide
• Rheumatoid arthritis guidelines 2, 3, 4 prioritize DMARDs (methotrexate as anchor drug), biologics, and targeted synthetic DMARDs
• Early arthritis guidelines 5 emphasize rapid DMARD initiation within 3 months
• Spondyloarthritis guidelines 6, 7 recommend NSAIDs as first-line with DMARDs for peripheral disease

FDA-Approved Indication

The FDA drug label 8 clearly indicates lacosamide is approved only for epilepsy, not for pain or arthritis conditions.

Limited Clinical Evidence in Humans

While animal studies show potential:

• Preclinical research demonstrates lacosamide reduces pain behavior in rat osteoarthritis models 9, 10, 11
• A 2026 study showed collagen II hydrogel-delivered lacosamide reduced cartilage degeneration in mice 9

However, human clinical data is problematic:

• A 2024 randomized controlled trial in neuropathic pain showed lacosamide had no effect on the primary outcome (average pain reduction) 12
• A 2026 systematic review found only modest pain reduction with high dropout rates and common adverse effects in neuropathic pain trials 13
• No published clinical trials exist for lacosamide in arthritis patients

What Should Be Used Instead

For Osteoarthritis:

1. Core treatments (all patients): Exercise, weight loss if overweight, patient education 1
2. First-line pharmacologic: Paracetamol regularly dosed
3. Second-line: Topical NSAIDs (for knee/hand), then oral NSAIDs/COX-2 inhibitors at lowest effective dose
4. Adjunctive: Intra-articular corticosteroid injections for moderate-to-severe pain

For Inflammatory Arthritis (RA, Early Arthritis):

1. Immediate referral to rheumatologist within 6 weeks of symptom onset 5
2. First-line DMARD: Methotrexate as anchor drug, started within 3 months 5, 2
3. Escalation: Add biologic or targeted synthetic DMARD if inadequate response
4. Symptomatic relief: NSAIDs at minimum effective dose for shortest duration 5

For Peripheral Spondyloarthritis:

1. Monoarthritis: Corticosteroid injections 7
2. Polyarthritis/oligoarthritis: Standard DMARDs (sulfasalazine may be considered) 6
3. NSAIDs: Can be added at lowest effective dose 7

Critical Caveat

The disconnect between promising preclinical data 9, 10, 11 and lack of human clinical trials represents a significant translational gap. Until properly designed randomized controlled trials demonstrate efficacy and safety in arthritis patients, lacosamide remains an investigational agent only and should not be prescribed for arthritis in clinical practice.